Keywords: Seattle Genetics, Adcetris, Takeda, Millennium, Hodgkin lymphoma, ALCL, Brentiximab vedotin

US FDA approves Seattle Genetics’ Adcetris to treat two types of lymphoma

Article | 22 August 2011

Print This

Shares of US biotech firm Seattle Genetics Nasdaq: SGEN) gained 8% to $15.09 late Friday, after the US Food and Drug Administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in